Barclays analyst Matt Miksic raised the firm’s price target on Intuitive Surgical to $430 from $385 and keeps an Overweight rating on the shares following the Q4 report. After much anticipation, the company finally announced its next generation da Vinci 5 robot, which is now pending FDA clearance, the analyst tells investors in a research note. The firm expects the announcement to be a positive for the stock, partially offset by tempered new system growth in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ISRG:
- Intuitive Surgical (NASDAQ:ISRG) Clears 52-Week High; Da Vinci 5 Coming Soon
- Intuitive (NASDAQ:ISRG) Gains after Better-than-Expected Q4 Results
- Intuitive Surgical Sees FY24 procedure growth 13%-16%
- Intuitive Surgical says da Vinci 5 will join existing robotic surgery portfolio
- Intuitive Surgical jumps 9% to $405.48 after Q4 results beat estimates
